(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Cabaletta Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CABA's revenue for 2028 to be $1,770,934,225, with the lowest CABA revenue forecast at $1,770,934,225, and the highest CABA revenue forecast at $1,770,934,225. On average, 2 Wall Street analysts forecast CABA's revenue for 2029 to be $7,002,040,507, with the lowest CABA revenue forecast at $1,232,042,492, and the highest CABA revenue forecast at $12,772,038,522.
In 2030, CABA is forecast to generate $18,042,724,423 in revenue, with the lowest revenue forecast at $6,750,862,157 and the highest revenue forecast at $29,334,586,688.